Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980023/S141

Pamira S 60 428768 Pamira S 65 428769 Pamira S 75 428770 Pamira SD 60/16 428771 Pamira SD 65/16 428772 Pamira SD 65/18 4

Biotronik, Inc. · Decision date Oct 29, 2025

FDA DECISIONP980023/S141

What did the FDA decide?

FDA records P980023/S141 as a supplement to PMA P980023, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 29, 2025.

FDA approval order statement

to implement an alternate supplier as well as minor dimensional changes and an inspection change for the locking screw component of DF4 connectors in the subject defibrillation leads
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 29, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P980023/S141
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
OK30
Decision date
Oct 29, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P980023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980023 · Original PMA

    PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

  2. P980023/S137 · Related supplement

    Ilivia Neo 7 VR-T DX; Ilivia Neo 7 VR-T; Intica Neo 7 VR-T DX; Intica Neo 7 VR-T; Intica Neo 5 VR-T DX; Intica Neo 5 VR-

  3. P980023/S141 received

    Application receipt date recorded by FDA.

  4. P980023/S138 · Related supplement

    Ilivia Neo 7 VR-T DX; Ilivia Neo 7 VR-T; Intica Neo 7 VR-T DX; Intica Neo 7 VR-T; Intica Neo 5 VR-T DX; Intica Neo 5 VR-

  5. P980023/S139 · Related supplement

    Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569

  6. P980023/S141 · FDA decision

    30-Day Notice

  7. P980023/S136 · Related supplement

    Acticor Sky VR-T 481989, Rivacor Sky VR-T 481984, Rivacor Rise VR-T 482020, Rivacor Aura VR-T 482015, Acticor Sky VR-T D

  8. P980023/S143 · Related supplement

    PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

  9. P980023/S142 · Related supplement

    PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM

  10. P980023/S144 · Related supplement

    Acticor Sky VR-T (481989); Rivacor Sky VR-T (481984); Rivacor Rise VR-T (482020); Rivacor Aura VR-T (482015); Acticor Sk

  11. P980023/S145 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  12. P980023/S147 · Related supplement

    Acticor Sky VR-T (481989); Rivacor Sky VR-T (481984); Rivacor Rise VR-T (482020); Rivacor Aura VR-T (482015); Acticor Sk

  13. P980023/S148 · Related supplement

    Plexa ProMRI S 60, Plexa ProMRI S 65, Plexa ProMRI S 75, Plexa ProMRI SD 60/16, Plexa ProMRI SD 65/16, Plexa ProMRI SD 6

  14. P980023/S150 · Related supplement

    Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6

  15. P980023/S146 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  16. P980023/S140 · Related supplement

    Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569

  17. P980023/S151 · Related supplement

    Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva

  18. P980023/S149 · Related supplement

    Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D

  19. P980023/S152 · Related supplement

    Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-

  20. P980023/S153 · Related supplement

    Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri

Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980023

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik, Inc.PMA approvalOct 27, 1998FDA
Biotronik, Inc.PMA supplementSep 15, 2025FDA
Biotronik, Inc.PMA supplementOct 1, 2025FDA
Biotronik, Inc.PMA supplementOct 16, 2025FDA
Biotronik, Inc.PMA supplementDec 18, 2025FDA
Biotronik, Inc.PMA supplementFeb 3, 2026FDA
Biotronik, Inc.PMA supplementFeb 11, 2026FDA
Biotronik, Inc.PMA supplementMar 5, 2026FDA
Biotronik, Inc.PMA supplementMay 7, 2026FDA
Biotronik, Inc.PMA supplementJun 24, 2026FDA
Biotronik, Inc.PMA supplementJul 1, 2026FDA
Biotronik, Inc.PMA supplementSep 10, 2026FDA
Biotronik, Inc.PMA supplementSep 17, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementSep 25, 2026FDA
Biotronik, Inc.PMA supplementOct 9, 2026FDA
Biotronik, Inc.PMA supplementOct 13, 2026FDA
Biotronik, Inc.PMA supplementOct 22, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records